Linked Life Data

21233244

Source:http://linkedlifedata.com/resource/pubmed/id/21233244

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2011-1-14
pubmed:abstractText
The incidence rate of the myelodysplastic syndromes (MDS) in the United States is approximately 3.4 per 100,000 people, accounting for more than 10,000 new diagnoses annually and an estimated 60,000 people living with the disease. Common risk factors for developing MDS include advanced age, male gender, and antecedent exposure to chemotherapy or radiation as treatment for other cancers, which alone accounts for 10% of MDS cases. Patients with MDS typically are diagnosed when they are in their 70s, have significant cytopenias, and have substantive transfusion needs. Erythropoiesis stimulating agents are used by more than 50% of patients, although the use of disease-modifying agents is increasing, and may ultimately have an impact on the number of patients living with MDS.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1540-1413
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
57-63
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010.
pubmed:affiliation
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Ohio 44195, USA. sekerem@ccf.org
pubmed:publicationType
Journal Article